Role of favipiravir in the treatment of COVID-19

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

(2020) Guangdi Li et al.   NATURE REVIEWS DRUG DISCOVERY

Another Decade, Another Coronavirus

(2020) Stanley Perlman   NEW ENGLAND JOURNAL OF MEDICINE

Favipiravir, an anti-influenza drug against life-threatening RNA virus infections

(2020) Kimiyasu Shiraki et al.   PHARMACOLOGY & THERAPEUTICS

Prioritisation of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

(2020) Usman Arshad et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS‐CoV‐2"

(2020) Yin‐Xiao Du et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection

(2020) Yin‐Xiao Du et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak

(2020) Tao Zhang et al.   CURRENT BIOLOGY

Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID‐19)

(2020) J. Wu et al.   JOURNAL OF INTERNAL MEDICINE

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of antiviral drugs to reduce COVID-19 transmission

(2020) Oriol Mitjà et al.   Lancet Global Health

A prospect on the use of antiviral drugs to control local outbreaks of COVID-19

(2020) Andrea Torneri et al.   BMC Medicine

Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus Disease 2019

(2020) Reed Magleby et al.   CLINICAL INFECTIOUS DISEASES

Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis

(2020) Anne Weiss et al.   EBioMedicine

The Rationale for Potential Pharmacotherapy of COVID-19

(2020) Maha Saber-Ayad et al.   Pharmaceuticals

Influenza virus polymerase inhibitors in clinical development

(2019) Frederick G. Hayden et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection

(2019) Yeming Wang et al.   JOURNAL OF INFECTIOUS DISEASES

Favipiravir as a potential countermeasure against neglected and emerging RNA viruses

(2018) Leen Delang et al.   ANTIVIRAL RESEARCH

The mechanism of resistance to favipiravir in influenza

(2018) Daniel H. Goldhill et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

(2017) Yousuke FURUTA et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)—Sierra Leone, 2014

(2016) Chang-Qing Bai et al.   CLINICAL INFECTIOUS DISEASES

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

(2016) Vincent Madelain et al.   CLINICAL PHARMACOKINETICS

Favipiravir: A New Medication for the Ebola Virus Disease Pandemic

(2014) Takashi Nagata et al.   Disaster Medicine and Public Health Preparedness

Broad Spectrum Antiviral Activity of Favipiravir (T-705): Protection from Highly Lethal Inhalational Rift Valley Fever

(2014) Amy L. Caroline et al.   PLoS Neglected Tropical Diseases

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

(2013) Yousuke Furuta et al.   ANTIVIRAL RESEARCH

T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro

(2013) T. Baranovich et al.   JOURNAL OF VIROLOGY

The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus Polymerase

(2013) Zhinan Jin et al.   PLoS One